{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T16:01:00Z","timestamp":1785427260060,"version":"3.56.0"},"posted":{"date-parts":[[2025,11,20]]},"group-title":"Neuroscience","reference-count":100,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"award":["R01NS110694"],"award-info":[{"award-number":["R01NS110694"]}],"id":[{"id":"https:\/\/ror.org\/01s5ya894","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,11,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>\n                  Huntington\u2019s disease (HD) is a devastating autosomal dominant neurodegenerative disease that manifests with progressive motor, cognitive, and psychological impairments. HD is caused by a polyQ (CAG) repeat expansion in the huntingtin (\n                  <jats:italic>HTT<\/jats:italic>\n                  ) gene, leading to the misfolding and aggregation of mutant HTT protein (mHTT) and the preferential degeneration of the striatum. Previously in our lab, we identified Protein Kinase CK2 as an important kinase involved in the pathophysiology of HD. Specifically, the alpha prime catalytic subunit of CK2 (CK2\u03b1\u2019) is upregulated in HD, and genetic depletion of CK2\u03b1\u2019 in HD mice results in improved motor behavior, decreased mutant Htt aggregation, and improved neuronal function. Silmitasertib (CX-4945) is an FDA designated orphan drug that inhibits CK2. This study aims to investigate whether CX-4945 treatment ameliorates HD pathology. We treated prodromal and late symptomatic HD mice, and used a variety of immunohistochemical, biochemical, physiological and behavioral approaches. We found that CX-4945 presented benefits in the amelioration of HD pathophysiology in both treated groups. Importantly, we found CX-4945 decreased mHtt aggregation, increased DARPP-32 expression and excitatory synapse density, restored homeostatic astrocyte phenotypes and ameliorated neuroinflammation and microgliosis, altogether resulting in improved motor behavior. These results support CX-4945 as a strong candidate for a targeted therapy to treat HD.\n                <\/jats:p>","DOI":"10.1101\/2025.11.19.689275","type":"posted-content","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T16:40:15Z","timestamp":1763656815000},"source":"Crossref","is-referenced-by-count":0,"title":["Silmitasertib, an FDA-designated orphan CK2 Inhibitor, ameliorates neuropathology and motor dysfunction in a Huntington\u2019s disease mouse model"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2027-7018","authenticated-orcid":false,"given":"Ross J.","family":"Pelzel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaya A.","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7730-6097","authenticated-orcid":false,"given":"Nicholas B.","family":"Rozema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9427-3534","authenticated-orcid":false,"given":"Melissa A.","family":"Solem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1136-5462","authenticated-orcid":false,"given":"Rocio","family":"Gomez-Pastor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2025112323550897000_2025.11.19.689275v1.1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90585-E"},{"issue":"1","key":"2025112323550897000_2025.11.19.689275v1.2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1750-1326-1-19","article-title":"Multiple pathways contribute to the pathogenesis of Huntington disease","volume":"1","year":"2006","journal-title":"Molecular Neurodegeneration"},{"issue":"4","key":"2025112323550897000_2025.11.19.689275v1.3","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1750-3639.1992.tb00709.x","article-title":"New insights into the clinical features, pathogenesis and molecular genetics of Huntington disease","volume":"2","year":"1992","journal-title":"Brain Pathol"},{"key":"2025112323550897000_2025.11.19.689275v1.4","doi-asserted-by":"crossref","unstructured":"Jia Q , Li S , Li XJ , Yin P . Neuroinflammation in Huntington\u2019s disease: From animal models to clinical therapeutics. Front Immunol [Internet]. 2022 Dec 22 [cited 2025 June 8];13. Available from: https:\/\/www.frontiersin.org\/journals\/immunology\/articles\/10.3389\/fimmu.2022.1088124\/full","DOI":"10.3389\/fimmu.2022.1088124"},{"key":"2025112323550897000_2025.11.19.689275v1.5","unstructured":"In a first, a gene therapy seems to slow Huntington disease [Internet]. [cited 2025 Nov 10]. Available from: https:\/\/www.science.org\/content\/article\/first-gene-therapy-seems-slow-huntington-disease"},{"issue":"8083","key":"2025112323550897000_2025.11.19.689275v1.6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/d41586-025-03139-9","article-title":"Huntington\u2019s disease treated for first time using gene therapy","volume":"646","year":"2025","journal-title":"Nature"},{"key":"2025112323550897000_2025.11.19.689275v1.7","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2023.1094503"},{"issue":"3","key":"2025112323550897000_2025.11.19.689275v1.8","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1177\/18796397251344173","article-title":"The role of astrocytes in human Huntington\u2019s disease pathology","volume":"14","year":"2025","journal-title":"J Huntingtons Dis"},{"issue":"1","key":"2025112323550897000_2025.11.19.689275v1.9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40478-020-0880-6","article-title":"Single-nucleus RNA-seq identifies Huntington disease astrocyte states","volume":"8","year":"2020","journal-title":"Acta Neuropathol Commun"},{"key":"2025112323550897000_2025.11.19.689275v1.10","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac068"},{"issue":"1","key":"2025112323550897000_2025.11.19.689275v1.11","doi-asserted-by":"crossref","first-page":"105732","DOI":"10.1016\/j.isci.2022.105732","article-title":"Single-nuclei transcriptome analysis of Huntington disease iPSC and mouse astrocytes implicates maturation and functional deficits","volume":"26","year":"2023","journal-title":"iScience"},{"key":"2025112323550897000_2025.11.19.689275v1.12","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.14977"},{"key":"2025112323550897000_2025.11.19.689275v1.13","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw8546"},{"issue":"1","key":"2025112323550897000_2025.11.19.689275v1.14","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s13311-023-01357-5","article-title":"Contribution of Glial Cells to Polyglutamine Diseases: Observations from Patients and Mouse Models","volume":"20","year":"2023","journal-title":"Neurotherapeutics"},{"key":"2025112323550897000_2025.11.19.689275v1.15","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddy363"},{"key":"2025112323550897000_2025.11.19.689275v1.16","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3693-15.2016"},{"issue":"11","key":"2025112323550897000_2025.11.19.689275v1.17","doi-asserted-by":"crossref","first-page":"dmm052002","DOI":"10.1242\/dmm.052002","article-title":"Modulation of SNARE-dependent exocytosis in astrocytes improves neuropathology in Huntington\u2019s disease","volume":"17","year":"2024","journal-title":"Disease Models & Mechanisms"},{"key":"2025112323550897000_2025.11.19.689275v1.18","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/978-981-13-9913-8_14","article-title":"Astrocytes in Huntington\u2019s Disease","volume":"1175","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"2025112323550897000_2025.11.19.689275v1.19","doi-asserted-by":"publisher","DOI":"10.1042\/bj20021469"},{"key":"2025112323550897000_2025.11.19.689275v1.20","doi-asserted-by":"publisher","DOI":"10.1016\/S1357-2725(96)00142-2"},{"key":"2025112323550897000_2025.11.19.689275v1.21","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.081778"},{"key":"2025112323550897000_2025.11.19.689275v1.22","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-008-0352-0"},{"issue":"1","key":"2025112323550897000_2025.11.19.689275v1.23","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41392-021-00567-7","article-title":"Protein kinase CK2: a potential therapeutic target for diverse human diseases","volume":"6","year":"2021","journal-title":"Sig Transduct Target Ther"},{"key":"2025112323550897000_2025.11.19.689275v1.24","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14405"},{"issue":"1","key":"2025112323550897000_2025.11.19.689275v1.25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s40478-022-01379-8","article-title":"CK2 alpha prime and alpha-synuclein pathogenic functional interaction mediates synaptic dysregulation in Huntington\u2019s disease","volume":"10","year":"2022","journal-title":"Acta Neuropathologica Communications"},{"key":"2025112323550897000_2025.11.19.689275v1.26","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2018.04.006"},{"issue":"1","key":"2025112323550897000_2025.11.19.689275v1.27","doi-asserted-by":"crossref","first-page":"26038","DOI":"10.1038\/s41598-024-75990-1","article-title":"CIGB-300 internalizes and impairs viability of NSCLC cells lacking actionable targets by inhibiting casein kinase-2 signaling","volume":"14","year":"2024","journal-title":"Sci Rep"},{"key":"2025112323550897000_2025.11.19.689275v1.28","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c01887"},{"issue":"6","key":"2025112323550897000_2025.11.19.689275v1.29","first-page":"1003","article-title":"Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy \u2013 potential clinical relevance","volume":"43","year":"2020","journal-title":"Cell Oncol (Dordr)"},{"issue":"1","key":"2025112323550897000_2025.11.19.689275v1.30","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/ph10010018","article-title":"CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target","volume":"10","year":"2017","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"2025112323550897000_2025.11.19.689275v1.31","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s10020-024-00937-1","article-title":"Impact of protein kinase CK2 downregulation and inhibition on oncomir clusters 17LJ\u223cLJ92 and 106bLJ\u223cLJ25 in prostate, breast, and head and neck cancers","volume":"30","year":"2024","journal-title":"Molecular Medicine"},{"key":"2025112323550897000_2025.11.19.689275v1.32","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2018.00146"},{"issue":"1","key":"2025112323550897000_2025.11.19.689275v1.33","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40478-022-01331-w","article-title":"Inhibition of CK2 mitigates Alzheimer\u2019s tau pathology by preventing NR2B synaptic mislocalization","volume":"10","year":"2022","journal-title":"Acta Neuropathologica Communications"},{"key":"2025112323550897000_2025.11.19.689275v1.34","first-page":"57","article-title":"Parkinson\u2019s disease-implicated kinases in the brain; insights into disease pathogenesis","volume":"7","year":"2014","journal-title":"Front Mol Neurosci"},{"key":"2025112323550897000_2025.11.19.689275v1.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2007.08.027"},{"issue":"15","key":"2025112323550897000_2025.11.19.689275v1.36","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1016\/j.neuron.2025.04.027","article-title":"Selective removal of astrocytic PERK protects against glymphatic impairment and decreases toxic aggregation of \u03b2-amyloid and tau","volume":"113","year":"2025","journal-title":"Neuron"},{"key":"2025112323550897000_2025.11.19.689275v1.37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0049838"},{"issue":"8","key":"2025112323550897000_2025.11.19.689275v1.38","doi-asserted-by":"crossref","first-page":"10468","DOI":"10.1007\/s12035-025-04905-6","article-title":"Estradiol Mediates Astrocyte-Neuron Communication in the Hippocampus","volume":"62","year":"2025","journal-title":"Mol Neurobiol"},{"key":"2025112323550897000_2025.11.19.689275v1.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2019.12.026"},{"key":"2025112323550897000_2025.11.19.689275v1.40","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0265"},{"key":"2025112323550897000_2025.11.19.689275v1.41","doi-asserted-by":"publisher","DOI":"10.1101\/gad.319830.118"},{"key":"2025112323550897000_2025.11.19.689275v1.42","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-012-0112-2"},{"key":"2025112323550897000_2025.11.19.689275v1.43","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.120166397"},{"key":"2025112323550897000_2025.11.19.689275v1.44","doi-asserted-by":"crossref","unstructured":"Hamilton J , Farag M , Tabrizi SJ . Complementary insights into corticostriatal synapse loss and cognition in Huntington\u2019s disease. CR Med [Internet]. 2023 Dec 19 [cited 2025 Nov 10];4(12). Available from: https:\/\/www.cell.com\/cell-reports-medicine\/abstract\/S2666-3791(23)00508-6","DOI":"10.1016\/j.xcrm.2023.101314"},{"key":"2025112323550897000_2025.11.19.689275v1.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2021.105574"},{"key":"2025112323550897000_2025.11.19.689275v1.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2024.106752"},{"issue":"7","key":"2025112323550897000_2025.11.19.689275v1.47","first-page":"1255","article-title":"Loss of striatal 90-kDa ribosomal S6 kinase (Rsk) is a key factor for motor, synaptic and transcription dysfunction in Huntington\u2019s disease","volume":"1862","year":"2016","journal-title":"Biochimica et Biophysica Acta (BBA) -Molecular Basis of Disease"},{"key":"2025112323550897000_2025.11.19.689275v1.48","doi-asserted-by":"publisher","DOI":"10.1186\/s13041-019-0456-1"},{"key":"2025112323550897000_2025.11.19.689275v1.49","doi-asserted-by":"crossref","unstructured":"Mishra S , Kinoshita C , Axtman AD , Young JE. Evaluation of a Selective Chemical Probe Validates That CK2 Mediates Neuroinflammation in a Human Induced Pluripotent Stem Cell-Derived Microglial Model. Front Mol Neurosci [Internet]. 2022 June 14 [cited 2025 Nov 14];15. Available from: https:\/\/www.frontiersin.org\/journals\/molecular-neuroscience\/articles\/10.3389\/fnmol.2022.824956\/full","DOI":"10.3389\/fnmol.2022.824956"},{"key":"2025112323550897000_2025.11.19.689275v1.50","doi-asserted-by":"crossref","unstructured":"Larson SR , Bortell N , Illies A , Crisler WJ , Matsuda JL , Lenz LL. Myeloid Cell CK2 Regulates Inflammation and Resistance to Bacterial Infection. Front Immunol [Internet]. 2020 Dec 8 [cited 2025 Nov 14];11. Available from: https:\/\/www.frontiersin.org\/journals\/immunology\/articles\/10.3389\/fimmu.2020.590266\/full","DOI":"10.3389\/fimmu.2020.590266"},{"key":"2025112323550897000_2025.11.19.689275v1.51","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2017.00193"},{"key":"2025112323550897000_2025.11.19.689275v1.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.104963"},{"key":"2025112323550897000_2025.11.19.689275v1.53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2023.578243"},{"issue":"3","key":"2025112323550897000_2025.11.19.689275v1.54","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1177\/18796397251338207","article-title":"Neuroinflammation in Huntington\u2019s disease: Causes, consequences, and treatment strategies","volume":"14","year":"2025","journal-title":"J Huntingtons Dis"},{"key":"2025112323550897000_2025.11.19.689275v1.55","doi-asserted-by":"crossref","unstructured":"Vidal-Itriago A , Radford RAW , Aramideh JA , Maurel C , Scherer NM , Don EK , et al. Microglia morphophysiological diversity and its implications for the CNS. Front Immunol [Internet]. 2022 Oct 19 [cited 2025 Nov 10];13. Available from: https:\/\/www.frontiersin.org\/journals\/immunology\/articles\/10.3389\/fimmu.2022.997786\/full","DOI":"10.3389\/fimmu.2022.997786"},{"key":"2025112323550897000_2025.11.19.689275v1.56","unstructured":"Pelzel R , Brown TG , Gomez-Pastor R . Astrocyte heterogeneity and gliosis in Huntington\u2019s disease: Histopathological insights into striatal and white matter pathology. Histol Histopathol. 2025 July 21;18971."},{"key":"2025112323550897000_2025.11.19.689275v1.57","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.052020999"},{"key":"2025112323550897000_2025.11.19.689275v1.58","doi-asserted-by":"publisher","DOI":"10.1002\/jemt.10303"},{"key":"2025112323550897000_2025.11.19.689275v1.59","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2021.04.035"},{"key":"2025112323550897000_2025.11.19.689275v1.60","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40035-023-00372-y","article-title":"\u03b1-Synuclein-carrying astrocytic extracellular vesicles in Parkinson pathogenesis and diagnosis","volume":"12","year":"2023","journal-title":"Transl Neurodegener"},{"key":"2025112323550897000_2025.11.19.689275v1.61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00037-1"},{"issue":"10","key":"2025112323550897000_2025.11.19.689275v1.62","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1111\/cns.14223","article-title":"Megf10-related engulfment of excitatory postsynapses by astrocytes following severe brain injury","volume":"29","year":"2023","journal-title":"CNS Neuroscience & Therapeutics"},{"key":"2025112323550897000_2025.11.19.689275v1.63","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez-Ortega K , Canul-Euan AA , Solis-Paredes JM , Borboa-Olivares H , Reyes-Mu\u00f1oz E , Estrada-Gutierrez G , et al. S100B actions on glial and neuronal cells in the developing brain: an overview. Front Neurosci [Internet]. 2024 July 4 [cited 2025 Nov 10];18. Available from: https:\/\/www.frontiersin.org\/journals\/neuroscience\/articles\/10.3389\/fnins.2024.1425525\/full","DOI":"10.3389\/fnins.2024.1425525"},{"issue":"1\u20132","key":"2025112323550897000_2025.11.19.689275v1.64","first-page":"131","article-title":"Protein kinase CK2 impact on intracellular calcium homeostasis in prostate cancer","volume":"470","year":"2020","journal-title":"Mol Cell Biochem"},{"issue":"2","key":"2025112323550897000_2025.11.19.689275v1.65","doi-asserted-by":"crossref","first-page":"250","DOI":"10.5056\/jnm22052","article-title":"Protein Kinase CK2 Modulates the Calcium Sensitivity of Type 3 Small-conductance Calcium-activated Potassium Channels in Colonic Platelet-derived Growth Factor Receptor Alpha-positive Cells From Streptozotocin-induced Diabetic Mice","volume":"29","year":"2023","journal-title":"J Neurogastroenterol Motil"},{"issue":"3","key":"2025112323550897000_2025.11.19.689275v1.66","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0167-4889(99)00058-0","article-title":"Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type","volume":"1450","year":"1999","journal-title":"Biochimica et Biophysica Acta (BBA) -Molecular Cell Research"},{"key":"2025112323550897000_2025.11.19.689275v1.67","first-page":"728052","article-title":"The Calcium-Dependent Interaction of S100B with Its Protein Targets","volume":"2010","year":"2010","journal-title":"Cardiovasc Psychiatry Neurol"},{"issue":"21","key":"2025112323550897000_2025.11.19.689275v1.68","doi-asserted-by":"crossref","first-page":"11661","DOI":"10.3390\/ijms252111661","article-title":"CK and LRRK2 Involvement in Neurodegenerative Diseases","volume":"25","year":"2024","journal-title":"International Journal of Molecular Sciences"},{"key":"2025112323550897000_2025.11.19.689275v1.69","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00809-8"},{"issue":"8","key":"2025112323550897000_2025.11.19.689275v1.70","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.3390\/biomedicines10081979","article-title":"Protein Kinase CK2 and Its Potential Role as a Therapeutic Target in Huntington\u2019s Disease","volume":"10","year":"2022","journal-title":"Biomedicines"},{"key":"2025112323550897000_2025.11.19.689275v1.71","doi-asserted-by":"publisher","DOI":"10.1038\/nrm.2017.73."},{"key":"2025112323550897000_2025.11.19.689275v1.72","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.582"},{"key":"2025112323550897000_2025.11.19.689275v1.73","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112198"},{"key":"2025112323550897000_2025.11.19.689275v1.74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0037929"},{"key":"2025112323550897000_2025.11.19.689275v1.75","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2014.131"},{"key":"2025112323550897000_2025.11.19.689275v1.76","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1306-x"},{"key":"2025112323550897000_2025.11.19.689275v1.77","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1801772115"},{"key":"2025112323550897000_2025.11.19.689275v1.78","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.15714"},{"key":"2025112323550897000_2025.11.19.689275v1.79","doi-asserted-by":"publisher","DOI":"10.1177\/1073858420972662"},{"key":"2025112323550897000_2025.11.19.689275v1.80","doi-asserted-by":"publisher","DOI":"10.1111\/cns.12844"},{"key":"2025112323550897000_2025.11.19.689275v1.81","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1205640"},{"key":"2025112323550897000_2025.11.19.689275v1.82","doi-asserted-by":"publisher","DOI":"10.1096\/fj.02-0473rev"},{"key":"2025112323550897000_2025.11.19.689275v1.83","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2004.07.158"},{"key":"2025112323550897000_2025.11.19.689275v1.84","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2013.02.011"},{"key":"2025112323550897000_2025.11.19.689275v1.85","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-013-0133-6"},{"key":"2025112323550897000_2025.11.19.689275v1.86","doi-asserted-by":"crossref","first-page":"1584577","DOI":"10.3389\/fimmu.2025.1584577","article-title":"Astrocyte-mediated inflammatory responses in traumatic brain injury: mechanisms and potential interventions","volume":"16","year":"2025","journal-title":"Front Immunol"},{"key":"2025112323550897000_2025.11.19.689275v1.87","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2020.08.012"},{"key":"2025112323550897000_2025.11.19.689275v1.88","doi-asserted-by":"crossref","unstructured":"Wakida NM , Lau AL , Nguyen J , Cruz GMS , Fote GM , Steffan JS , et al. Diminished LC3-Associated Phagocytosis by Huntington\u2019s Disease Striatal Astrocytes. J Huntingtons Dis. 11(1):25\u201333.","DOI":"10.3233\/JHD-210502"},{"key":"2025112323550897000_2025.11.19.689275v1.89","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-53414-9"},{"key":"2025112323550897000_2025.11.19.689275v1.90","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22084065"},{"key":"2025112323550897000_2025.11.19.689275v1.91","doi-asserted-by":"publisher","DOI":"10.1038\/nature21029"},{"key":"2025112323550897000_2025.11.19.689275v1.92","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.10.073"},{"key":"2025112323550897000_2025.11.19.689275v1.93","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax3519"},{"key":"2025112323550897000_2025.11.19.689275v1.94","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2220551120"},{"key":"2025112323550897000_2025.11.19.689275v1.95","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2023.05.006"},{"key":"2025112323550897000_2025.11.19.689275v1.96","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2008.11.009"},{"key":"2025112323550897000_2025.11.19.689275v1.97","first-page":"929712","article-title":"S100B Protein in the Nervous System and Cardiovascular Apparatus in Normal and Pathological Conditions","volume":"2010","year":"2010","journal-title":"Cardiovasc Psychiatry Neurol"},{"key":"2025112323550897000_2025.11.19.689275v1.98","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.29.15_suppl.3087"},{"issue":"21","key":"2025112323550897000_2025.11.19.689275v1.99","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1182\/blood.V120.21.2471.2471","article-title":"CX-4945, an Orally Bioavailable Selective Inhibitor of Casein Kinase 2 (CK2), Exhibits Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Exhibits Synergy When Combined with the PI3K-\u0394 Inhibitor GS-1101 or Fludarabine","volume":"120","year":"2012","journal-title":"Blood"},{"key":"2025112323550897000_2025.11.19.689275v1.100","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.232"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.11.19.689275","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T05:08:35Z","timestamp":1782277715000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2025.11.19.689275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":100,"URL":"https:\/\/doi.org\/10.1101\/2025.11.19.689275","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1016\/j.neurot.2026.e00859","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2025,11,20]]},"subtype":"preprint"}}